Printer-friendly versionPrinter-friendly version

A viral hepatitis free future : how to make it feasible and affordable.

June 5-6, 2015- London, United Kingdom

Objectives of the meeting:

  • Determine the feasibility of hepatitis C elimination goals for the EURO region;
  • Investigate European countries current trends in hepatitis C transmission and disease, overview of health care system, capacity for the prevention, care, and treatment of Hepatitis C and the status of implementation of a National/regional hepatitis plans (example of experiences in different European countries);
  • Overview of cost effectiveness of treatment based interventions and resources needed;
  • List cost-effective strategy in Europe: case studies and country examples;
  • Overview of financial mechanisms to make treatment affordable in Europe: case studies and country examples;
  • Review the Hepatitis Control plan of different international organisations (WHO, WHO Euro, ECDC, WHA, …);
  • Where does viral hepatitis fit in the EU projects and calls?;
  • What is the economic impact of viral hepatitis Control?;
  • Discuss elimination and elimination goals of viral hepatitis. Is it feasible, at what price and what is needed to make it happen?
  • What are the lessons learnt from other infectious diseases elimination programmes;
  • Investigate how decision makers can be convinced to change the healthcare priorities for viral hepatitis;
  • What can we learn from the viral hepatitis C elimination programmes for the hepatitis B situation?

    FRIDAY, June 5, 2015

    SESSION 1 : THE FEASIBILITY OF HEPATITIS C ELIMINATION GOALS FOR THE WHO EURO REGION ; OPENING AND OBJECTIVES;
    Chair: Daniel Lavanchy and Hans Blystad

    09:00-09:20 Introduction of participants

    09:20-09:40
    WHO: WHO Global Hepatitis Strategy: Moving toward elimination of hepatitis B and C - 925kb (.pdf)
    Stefan Wiktor WHO Headquarter

    09:40-10:00
    WHO Euro: WHO-EURO: European regional goals for hepatitis B and C elimination - 406kb (.pdf)
    Antons Mozalevskis, WHO Euro

    WHO Euro: Regional plan on Hepatitis B control - 30kb (.pdf)
    Liudmila Mosina, WHO Euro

    10:00-10:20 Discussion on elimination goals

    10:20-10:40 Coffee break

    SESSION 2: HEPATITIS CONTROL PLAN, WHERE WILL WE MAKE THE DIFFERENCE IN THE NEXT 5 YEARS
    Chair: Pierre Van DammeRui Tato Marinho

    The panel members

    10:40-10:50 WHO - 149kb (.pdf) - Stefan Wiktor

    10:50-11:00 WHO EURO- 330kb (.pdf) - Antons Mozalevskis or Luidmila Mosina

    11:00-11:10 ECDC- 509kb (.pdf) - Erika Duffell

    11:10-11:20 ELPA- 3.7Mb (.pdf) - Margaret Walker

    11:20-11:30 EASL - Fiona Godfrey

    11:30-12:05 Question and discussion

    12:05-13:20 Lunch

    SESSION 3: COST/PRICE OF AN HEPATITIS FREE WORLD? COST EFFECTIVENESS AND ECONOMIC IMPACT OF SCREENING AND TREATMENT OF HEPATITIS C PATIENTS
    Chair: Mira Kojouharova – David Goldberg

    13:20 -13:40
    Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable - 729kb (.pdf)
    Deuffic-Burban Sylvie, Inserm ATIP-AVENIR, France - Health economics

    13:40-14:00
    The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus - 579kb (.pdf)
    David Rein NORC, University Chicago, USA

    14:00-14:20
    Burden of hepatitis C in Europe- The Case of France and Romania - 865kb (.pdf)
    Gustaf Ortsäter, Quantify Research, Sweden

    14:20-14:40 Question and discussion

    14:40-15:10 coffee break

    SESSION 5 :: EUROPEAN COUNTRIES CURRENT TRENDS IN HEPATITIS C TRANSMISSION AND DISEASE, OVERVIEW OF HEALTH CARESYSTEM, CAPACITY FOR THE PREVENTION, CARE, AND TREATMENT OF HEPATITIS C AND THE STATUS OF IMPLEMENTATION OF NATIONAL/REGIONAL HEPATITIS PLANS (EXAMPLE OF EXPERIENCES IN DIFFERENT EUROPEAN COUNTRIES)
    Parallel Groups : Chair Middle income countries: Angela Dominguez – Liudmila Mosina Chair High income countries: Heléne Norder –Erika Duffell

    15:10 - 15:25
    Georgia- 276kb (.pdf)
    Maia Tsereteli
    Greece - 670kb (.pdf)
    Angelos Hatzakis

    15:25 - 15:40
    Albania
    Silvia Bino
    Belgium- 901kb (.pdf)
    Yves Horsmans

    15:40 - 15:55
    Bulgaria - 139kb (.pdf)
    Stanimir Hasurdjiev
    Scotland – David Goldberg

    15:55 - 16:10
    Romania - 763kb (.pdf)
    Odette Popovici
    Current trends in hepC prevention, care and treatment Slovenia
    Mojca Matičič

    16:10-16:40 Question and discussion

    Rapporteur of each group will present the highlights

    SESSION 5 : PART I: ACCESS TO TREATMENT – FINANCE AND POLICY INITIATIVES
    Chair: Françoise Roudot-Thoraval – Wolfgang Jilg

    17:10-17:30
    What are the health system requirements (other than inexpensive drugs)and service delivery model of hepatitis care to scale up treatment
    Philippa Easterbrook, WHO Headquarter

    17:30-17:50
    New WHO report : Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research - 435kb (.pdf)
    Panos Kanavos, London School of Economics

    17:50-18:10
    Alternative models of funding innovation in health care - 696kb (.pdf)
    Panos Kanavos, London School of Economics

    18:30 End of day one

    SATURDAY, June 6, 2015

    SESSION 3 5BIS) : COST/PRICE OF AN HEPATITIS FREE WORLD? COST EFFECTIVENESS AND ECONOMIC IMPACT OF SCREENING AND TREATMENT OF HEPATITIS C PATIENTS
    Chair: Mira Kojouharova – David Goldberg

    09:00-09:20 Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? - 1.4Mb (.pdf)
    Livio Garattini, Mario Negri Institute for Pharmacological Research, Italy

    Session 5: Access to treatment – Finance and policy initiatives
    Chair: Daniel Shouval- David Rein

    09:20-09:40 Voluntary licensing and tiered pricing, the role of the pharmaceutical companies
    Graeme Robertson, Gilead

    09:40-10:00 New treatments for hepatitis C: strategies for achieving universal access - 1.1Mb (.pdf)
    Céline Grillon, Médecins du Monde

    10:00-10:20 Innovative finance initiative to tackle HCV in Europe
    Angelos Hatzakis, HepB and Hep C policy association
    Rob Walton, Wisper

    10:20-10:40 Question and discussion

    10:40-11:00 coffee break

    SESSION 6: HOW VIRAL HEPATITS PREVENTION AND TREATMENT CAN BE FUNDED IN THE NEAR FUTURE; LESSONS LEARNT FROM OTHER DISEASES OR HEALTH PROGRAMMES
    Chair: Tatjana Reic – Stefan Wiktor

    11:00-11:20 Global fund Aids TB Malaria
    Michael Borowitz

    11:20-11:40 GAVI- 175kb (.pdf)
    Mark Kane

    11:40-12:05 Question and discussion

    12:05-13:25 Lunch

    SESSION 7: DEBATE: HOW CAN DECISION MAKERS AND POTENTIAL FUNDERS BE CONVINCED TO CHANGE HEALTH PRIORITIES?
    Chair: Mark Kane – John Ward

    13:25-13:45 Introduction sessions:  Available Hepatitis Information: how can this be used to convince decision makers and potential funders. Example of available information 739kb (.pdf)
    Homie Razavi Centre for disease analysis USA

    13:45-14:30 discussion on participants survey

    14:30-15:00 Coffee break

    SESSION 8: CONCLUSIONS OF THE MEETING
    (David FitzSimons – rapporteur)

    Chair: Johannes Hallauer – Alessandro Zanetti

    15:00-16:00 Conclusions of the meeting 46kb (.pdf)

    Tags: